Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ICMRA

- PMLiVE

BTG rises on FDA approval of varicose vein therapy

Varithena receives green light in US

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

- PMLiVE

Nexavar cleared for thyroid cancer by FDA

Bayer and Onyx win expansion of oncology drug’s use in US

- PMLiVE

New FDA guidance for advertising

Clarifies circumstances when drug names need to be mentioned

- PMLiVE

Ariad’s cancer drug to remain on EU market

But EMA restricts use of Iclusig due to blood clot risk

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

- PMLiVE

FDA turns down Forest/Gedeon Richter’s antipsychotic

US regulator wants more information for cariprazine

- PMLiVE

Fox Communications leads comms for UK obesity week

Will run ‘Let’s turn obesity around’ campaign in January

- PMLiVE

AZ drug for opioid constipation starts FDA review

Naloxegol on course to compete with Takeda’s Amitiza

EU flag

EMA drug data to address HTA needs

EU regulator agrees joint work plan with EUnetHTA

- PMLiVE

Teva withdraws US filing for cancer biologic

FDA requests more data for balugrastim

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links